by European Public Health Alliance | Nov 14, 2020 | Cancer, Universal Access and Affordable Medicines | Analysis & Opinion
Guest article | Lydie Meheus PhD, Managing Director, Belgian Anticancer FundCancer patients want to have access to the best available treatment and they want it fast, as in many cases they expect it to be lifesaving.Unfortunately, the current system to bring a new...
by Yannis Natsis | Nov 14, 2020 | Universal Access and Affordable Medicines | Analysis & Opinion
We have come a long way in a short period of time since the adoption of the groundbreaking June 2016 Council Conclusions on pharmaceuticals. The conclusions were a milestone for the access to medicines debate as they signaled the political acknowledgment of the series...
by Yannis Natsis | Jun 30, 2020 | COVID-19, Universal Access and Affordable Medicines | Analysis & Opinion, Universal Access and Affordable Medicines | Latest Developments
In recent weeks, there have been some notable developments in relation to the procurement of potential vaccines against COVID19. On June 3, France, Germany, the Netherlands and Italy announced the formation of the Inclusive Vaccine Alliance (IVA) in order to negotiate...
by Yannis Natsis | Apr 6, 2020 | COVID-19, Universal Access and Affordable Medicines | Analysis & Opinion
Download the article How will pharma price the products against COVID-19, be they anti-viral therapies and/or a vaccine? As the pandemic hits Europe and the U.S., pharma is firmly in the spotlight as society turns to them hoping that some therapeutics will be...
by Yannis Natsis | Feb 6, 2020 | Universal Access and Affordable Medicines | Analysis & Opinion
2020 is a special year for the EU policy world. During the second half of last year, we heard a lot about the overarching themes of the von der Leyen Commission. For the next eleven months, there will be a lot of pushing and turning – and lobbying money spent- to zoom...
by European Public Health Alliance | Oct 24, 2019 | Universal Access and Affordable Medicines | Analysis & Opinion
By Ellen ‘t Hoen LLM PhD, Medicines Law & Policy Patents and other forms of exclusive rights, such as data exclusivity and market exclusivity, are meant to stimulate innovation by rewarding innovators with temporary monopolies over their innovations. These...
